What Happened?
• On January 9, 2026, Aquestive announced it received a letter from the FDA, identifying deficiencies in its NDA application that preclude labeling discussions and post-market commitments for Anaphylm, for the emergency treatment of anaphylaxis.
Why it Matters:
• Today, in direct response to this news, Aquestive’s stock price fell by $2.18 (35.1%) per share to open at $4.03.
To receive more information, please fill out the form.
